---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-081202"
form_type: "8-K"
ticker: "EWTX"
cik: "0001710072"
company_name: "Edgewise Therapeutics, Inc."
filed_at: "2023-07-14T23:59:59+00:00"
generated_at: "2026-06-13T08:15:25.585482+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Edgewise receives Nasdaq notice for audit committee non-compliance; cure period until June 2024

## Summary
- Notice on July 10, 2023 from Nasdaq: audit committee fell below 3 members after Dr. Kenneth Harrison resigned from board and audit committee on June 19, 2023.
- Cure period: until earlier of next annual shareholders' meeting or June 19, 2024; if annual meeting before Dec 18, 2023, then compliance needed by Dec 18, 2023.
- Company intends to rely on cure period and is evaluating board and committee composition to regain compliance.
- Failure to cure could result in delisting; company may appeal to a Hearings Panel.

## SEC filing metadata
- accession: 0001104659-23-081202
- form_type: 8-K
- ticker: EWTX
- cik: 0001710072
- company_name: Edgewise Therapeutics, Inc.
- filed_at: 2023-07-14T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710072/000110465923081202/0001104659-23-081202-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710072/000110465923081202/tm2321301d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-081202
- JSON: https://secwatch.observer/filing/0001104659-23-081202.json
- Plain text: https://secwatch.observer/filing/0001104659-23-081202.txt

## Key facts
- Listing & Compliance Notices
  Edgewise Therapeutics, Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2), 5605(c)(4)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: audit committee
  - Rules: 5605(c)(2), 5605(c)(4)
  source text: July 10, 2023, Edgewise Therapeutics, Inc. (the “Company”) received a notice (the “Notice”) from The Nasdaq Stock Market LLC (the “Nasdaq”) stating that, as a result of the resignation of Kenneth Harrison, Ph.D. (the “Director Resignation”) from the Board of Directors of the Company (the “Board”) and the Audit Committee of the Board (the “Audit Committee”), effective June 19, 2023 (as previously disclosed), the Company is no longer in compliance with the Nasdaq Listing Rule 5605, including the Nasdaq Listing Rule 5605(c)(2), which requires the Audit Committee to consist of at least three membe
  evidence_url: https://www.sec.gov/Archives/edgar/data/1710072/000110465923081202/0001104659-23-081202-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.